Targeting the ubiquitin-proteasome system in atherosclerosis: Status Quo, challenges, and perspectives

Antioxidants and Redox Signaling

Volumn 21, Issue 17, 2014, Pages 2344-2363

  Wilck, Nicola ^a   Ludwig, Antje ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEASOME; PROTEASOME INHIBITOR; UBIQUITIN;

APOPTOSIS; ATHEROSCLEROSIS; AUTOPHAGY; CELL PROLIFERATION; DISEASE COURSE; EUKARYOTIC CELL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN HOMEOSTASIS; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; UBIQUITIN PROTEASOME SYSTEM; ANIMAL; ENZYMOLOGY; METABOLISM;

ANIMALS; ATHEROSCLEROSIS; HUMANS; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN;

EID: 84912536136     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2013.5805     Document Type: Review

References (206)

1. The 10 leading causes of death by broad income group (2008). World Health Organization (WHO), June 2011. http://www.who.int/mediacentre/factsheets/fs310/en/index.html
2. Adams J, Behnke M, Chen S, Cruickshank AA, Dick LR, Grenier L, Klunder JM, Ma YT, Plamondon L, and Stein RL. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 8: 333-338, 1998.
3. Ait-Oufella H, Taleb S, Mallat Z, and Tedgui A. Recent advances on the role of cytokines in atherosclerosis. Arterioscler Thromb Vasc Biol 31: 969-979, 2011.
4. Amanso AM, Debbas V, and Laurindo FR. Proteasome inhibition represses unfolded protein response and Nox4, sensitizing vascular cells to endoplasmic reticulum stressinduced death. PLoS One 6: e14591, 2011.
5. Arastu-Kapur S, Anderl JL, Kraus M, Parlati F, Shenk KD, Lee SJ, Muchamuel T, Bennett MK, Driessen C, Ball AJ, and Kirk CJ. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res 17: 2734-2743, 2011.
6. Avcu F, Ural AU, Cetin T, and Nevruz O. Effects of bortezomib on platelet aggregation and ATP release in human platelets, in vitro. Thromb Res 121: 567-571, 2008.
7. Azuma Y, TakadaM, MaedaM, Kioka N, and Ueda K. The COP9 signalosome controls ubiquitinylation of ABCA1. Biochem Biophys Res Commun 382: 145-148, 2009.
8. Barringhaus KG and Matsumura ME. The proteasome inhibitor lactacystin attenuates growth and migration of vascular smooth muscle cells and limits the response to arterial injury. Exp Clin Cardiol 12: 119-124, 2007.
9. Beck P, Dubiella C, and Groll M. Covalent and noncovalent reversible proteasome inhibition. Biol Chem 393: 1101-1120, 2012.
10. Bence NF, Sampat RM, and Kopito RR. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292: 1552-1555, 2001.
11. Berberian PA, Myers W, Tytell M, Challa V, and Bond MG. Immunohistochemical localization of heat shock protein-70 in normal-appearing and atherosclerotic specimens of human arteries. Am J Pathol 136: 71-80, 1990.
12. Bernassola F, Ciechanover A, and Melino G. The ubiquitin proteasome system and its involvement in cell death pathways. Cell Death Differ 17: 1-3, 2010.
13. Bieler S, Meiners S, Stangl V, Pohl T, and Stangl K. Comprehensive proteomic and transcriptomic analysis reveals early induction of a protective anti-oxidative stress response by low-dose proteasome inhibition. Proteomics 9: 3257-3267, 2009.
14. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, and Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 297: 842-857, 2007.
15. Bjornheden T, Levin M, Evaldsson M, and Wiklund O. Evidence of hypoxic areas within the arterial wall in vivo. Arterioscler Thromb Vasc Biol 19: 870-876, 1999.
16. Brand K, Page S, Rogler G, Bartsch A, Brandl R, Knuechel R, Page M, Kaltschmidt C, Baeuerle PA, and Neumeier D. Activated transcription factor nuclear factorkappa B is present in the atherosclerotic lesion. J Clin Invest 97: 1715-1722, 1996.
17. Broemer M and Meier P. Ubiquitin-mediated regulation of apoptosis. Trends Cell Biol 19: 130-140, 2009.
18. Bruick RK and McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294: 1337-1340, 2001.
19. Bulteau AL, Lundberg KC, Humphries KM, Sadek HA, Szweda PA, Friguet B, and Szweda LI. Oxidative modification and inactivation of the proteasome during coronary occlusion/reperfusion. J Biol Chem 276: 30057-30063, 2001.
20. Bulteau AL, Szweda LI, and Friguet B. Age-dependent declines in proteasome activity in the heart. Arch Biochem Biophys 397: 298-304, 2002.
21. Cai H and Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 87: 840-844, 2000.
22. Canty TG, Jr., Boyle EM, Jr., Farr A, Morgan EN, Verrier ED, and Pohlman TH. Oxidative stress induces NF-kappaB nuclear translocation without degradation of IkappaBalpha. Circulation 100: II361-II364, 1999.
23. Cenci S, Oliva L, Cerruti F, Milan E, Bianchi G, Raule M, Mezghrani A, Pasqualetto E, Sitia R, and Cascio P. Pivotal advance: protein synthesis modulates responsiveness of differentiating and malignant plasma cells to proteasome inhibitors. J Leukoc Biol 92: 921-931, 2012.
24. Chade AR, Herrmann J, Zhu X, Krier JD, Lerman A, and Lerman LO. Effects of proteasome inhibition on the kidney in experimental hypercholesterolemia. J Am Soc Nephrol 16: 1005-1012, 2005.
25. Chandel NS, McClintock DS, Feliciano CE, Wood TM, Melendez JA, Rodriguez AM, and Schumacker PT. Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1alpha during hypoxia: a mechanism of O2 sensing. J Biol Chem 275: 25130-25138, 2000.
26. Chapple SJ, Siow RC, and Mann GE. Crosstalk between Nrf2 and the proteasome: therapeutic potential of Nrf2 inducers in vascular disease and aging. Int J Biochem Cell Biol 44: 1315-1320, 2012.
27. Charo IF and Taub R. Anti-inflammatory therapeutics for the treatment of atherosclerosis. Nat Rev Drug Discov 10: 365-376, 2011.
28. Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, Maher ER, Pugh CW, Ratcliffe PJ, and Maxwell PH. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 275: 25733-25741, 2000.
29. Connolly G. The impact of bortezomib on the risk of thrombosis in multiple myeloma. Leuk Res 35: 145-146, 2011.
30. Cullen SJ, Ponnappan S, and Ponnappan U. Proteasome inhibition up-regulates inflammatory gene transcription induced by an atypical pathway of NF-kappaB activation. Biochem Pharmacol 79: 706-714, 2010.
31. Cuschieri J, Gourlay D, Garcia I, Jelacic S, and Maier RV. Implications of proteasome inhibition: an enhanced macrophage phenotype. Cell Immunol 227: 140-147, 2004.
32. Dagia NM and Goetz DJ. A proteasome inhibitor reduces concurrent, sequential, and long-term IL-1 beta-and TNFalpha-induced ECAM expression and adhesion. Am J Physiol Cell Physiol 285: C813-C822, 2003.
33. Dahlmann B. Role of proteasomes in disease. BMC Biochem 8 Suppl 1: S3, 2007.
34. Dahlmann B, Ruppert T, Kuehn L, Merforth S, and Kloetzel PM. Different proteasome subtypes in a single tissue exhibit different enzymatic properties. J Mol Biol 303: 643-653, 2000.
35. Davignon J and Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 109: III27-III32, 2004.
36. Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN, Jiang J, Laidig GJ, Lewis ER, Parlati F, Shenk KD, Smyth MS, Sun CM, Vallone MK, Woo TM, Molineaux CJ, and Bennett MK. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 67: 6383-6391, 2007.
37. Di Filippo C, Marfella R, and D'Amico M. Possible dual role of ubiquitin-proteasome system in the atherosclerotic plaque progression. J Am Coll Cardiol 52: 1350-1351; author reply 1351, 2008.
38. Dick TP, Nussbaum AK, Deeg M, Heinemeyer W, Groll M, Schirle M, Keilholz W, Stevanovic S, Wolf DH, Huber R, Rammensee HG, and Schild H. Contribution of proteasomal beta-subunits to the cleavage of peptide substrates analyzed with yeast mutants. J Biol Chem 273: 25637-25646, 1998.
39. Diebold I, Djordjevic T, Hess J, and Gorlach A. Rac-1 promotes pulmonary artery smooth muscle cell proliferation by upregulation of plasminogen activator inhibitor-1: role of NFkappaB-dependent hypoxia-inducible factor-1alpha transcription. Thromb Haemost 100: 1021-1028, 2008.
40. Ding WX, Ni HM, Gao W, Yoshimori T, Stolz DB, Ron D, and Yin XM. Linking of autophagy to ubiquitinproteasome system is important for the regulation of endoplasmic reticulum stress and cell viability. Am J Pathol 171: 513-524, 2007.
41. Dreger H, Westphal K, Weller A, Baumann G, Stangl V, Meiners S, and Stangl K. Nrf2-dependent upregulation of antioxidative enzymes: a novel pathway for proteasome inhibitor-mediated cardioprotection. Cardiovasc Res 83: 354-361, 2009.
42. Dreger H, Westphal K, Wilck N, Baumann G, Stangl V, Stangl K, and Meiners S. Protection of vascular cells from oxidative stress by proteasome inhibition depends on Nrf2. Cardiovasc Res 85: 395-403, 2010.
43. Drexler HC. The role of p27Kip1 in proteasome inhibitor induced apoptosis. Cell Cycle 2: 438-441, 2003.
44. Drexler HC, Risau W, and Konerding MA. Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells. FASEB J 14: 65-77, 2000.
45. Dzau VJ, Braun-Dullaeus RC, and Sedding DG. Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat Med 8: 1249-1256, 2002.
46. Fearon IM and Faux SP. Oxidative stress and cardiovascular disease: novel tools give (free) radical insight. J Mol Cell Cardiol 47: 372-381, 2009.
47. Feng B and Tabas I. ABCA1-mediated cholesterol efflux is defective in free cholesterol-loaded macrophages. Mechanism involves enhanced ABCA1 degradation in a process requiring full NPC1 activity. J Biol Chem 277: 43271-43280, 2002.
48. Feng B, Zhang Y, Mu J, Ye Z, Zeng W, Qi W, Luo Z, Guo Y, Yang X, and Yuan F. Preventive effect of a proteasome inhibitor on the formation of accelerated atherosclerosis in rabbits with uremia. J Cardiovasc Pharmacol 55: 129-138, 2010.
49. Friguet B and Szweda LI. Inhibition of the multicatalytic proteinase (proteasome) by 4-hydroxy-2-nonenal crosslinked protein. FEBS Lett 405: 21-25, 1997.
50. Fukai T. Targeting proteasome worsens atherosclerosis. Circ Res 101: 859-861, 2007.
51. Galkina E and Ley K. Leukocyte influx in atherosclerosis. Curr Drug Targets 8: 1239-1248, 2007.
52. Galkina E and Ley K. Vascular adhesion molecules in atherosclerosis. Arterioscler Thromb Vasc Biol 27: 2292-2301, 2007.
53. Gao L, Chen Q, Zhou X, and Fan L. The role of hypoxiainducible factor 1 in atherosclerosis. J Clin Pathol 65: 872-876, 2012.
54. Gautier EL, Huby T, Witztum JL, Ouzilleau B, Miller ER, Saint-Charles F, Aucouturier P, Chapman MJ, and Lesnik P. Macrophage apoptosis exerts divergent effects on atherogenesis as a function of lesion stage. Circulation 119: 1795-1804, 2009.
55. Glass CK and Witztum JL. Atherosclerosis. the road ahead. Cell 104: 503-516, 2001.
56. Glickman MH and Ciechanover A. The ubiquitinproteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 82: 373-428, 2002.
57. Goldberg AL. Protein degradation and protection against misfolded or damaged proteins. Nature 426: 895-899, 2003.
58. Goldstein JL and Brown MS. Regulation of the mevalonate pathway. Nature 343: 425-430, 1990.
59. Greijer AE and van der Wall E. The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J Clin Pathol 57: 1009-1014, 2004.
60. Griendling KK and FitzGerald GA. Oxidative stress and cardiovascular injury: Part I: basic mechanisms and in vivo monitoring of ROS. Circulation 108: 1912-1916, 2003.
61. Groll M, Bajorek M, Kohler A, Moroder L, Rubin DM, Huber R, Glickman MH, and Finley D. A gated channel into the proteasome core particle. Nat Struct Biol 7: 1062-1067, 2000.
62. Grune T, Jung T, Merker K, and Davies KJ. Decreased proteolysis caused by protein aggregates, inclusion bodies, plaques, lipofuscin, ceroid, and 'aggresomes' during oxidative stress, aging, and disease. Int J Biochem Cell Biol 36: 2519-2530, 2004.
63. Guo K, Andres V, and Walsh K. Nitric oxide-induced downregulation of Cdk2 activity and cyclin A gene transcription in vascular smooth muscle cells. Circulation 97: 2066-2072, 1998.
64. Hansson GK and Hermansson A. The immune system in atherosclerosis. Nat Immunol 12: 204-212, 2011.
65. Harrison D, Griendling KK, Landmesser U, Hornig B, and Drexler H. Role of oxidative stress in atherosclerosis. Am J Cardiol 91: 7A-11A, 2003.
66. Heink S, Ludwig D, Kloetzel PM, and Kruger E. IFNgamma-induced immune adaptation of the proteasome system is an accelerated and transient response. Proc Natl Acad Sci USA 102: 9241-9246, 2005.
67. Herrmann J, Edwards WD, Holmes DR, Jr., Shogren KL, Lerman LO, Ciechanover A, and Lerman A. Increased ubiquitin immunoreactivity in unstable atherosclerotic plaques associated with acute coronary syndromes. J Am Coll Cardiol 40: 1919-1927, 2002.
68. Herrmann J, Lerman LO, and Lerman A. On to the road to degradation: atherosclerosis and the proteasome. Cardiovasc Res 85: 291-302, 2010.
69. Herrmann J, Saguner AM, Versari D, Peterson TE, Chade A, Olson M, Lerman LO, and Lerman A. Chronic proteasome inhibition contributes to coronary atherosclerosis. Circ Res 101: 865-874, 2007.
70. Herrmann J, Soares SM, Lerman LO, and Lerman A. Potential role of the ubiquitin-proteasome system in atherosclerosis: aspects of a protein quality disease. J Am Coll Cardiol 51: 2003-2010, 2008.
71. Hipp MS, Urbich C, Mayer P, Wischhusen J, Weller M, Kracht M, and Spyridopoulos I. Proteasome inhibition leads to NF-kappaB-independent IL-8 transactivation in human endothelial cells through induction of AP-1. Eur J Immunol 32: 2208-2217, 2002.
72. Hiroi T, Deming CB, Zhao H, Hansen BS, Arkenbout EK, Myers TJ, McDevitt MA, and Rade JJ. Proteasome inhibitors enhance endothelial thrombomodulin expression via induction of Kruppel-like transcription factors. Arterioscler Thromb Vasc Biol 29: 1587-1593, 2009.
73. Hosoya T, Maruyama A, Kang MI, Kawatani Y, Shibata T, Uchida K, Warabi E, Noguchi N, Itoh K, and Yamamoto M. Differential responses of the Nrf2-Keap1 system to laminar and oscillatory shear stresses in endothelial cells. J Biol Chem 280: 27244-27250, 2005.
74. Howlett GJ and Moore KJ. Untangling the role of amyloid in atherosclerosis. Curr Opin Lipidol 17: 541-547, 2006.
75. Huang LE, Arany Z, Livingston DM, and Bunn HF. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J Biol Chem 271: 32253-32259, 1996.
76. Hueper W. Artereosclerosis: the anoxemia theory. Arch Pathol 38: 173-205, 1944.
77. Ichikawa HT, Conley T, Muchamuel T, Jiang J, Lee S, Owen T, Barnard J, Nevarez S, Goldman BI, Kirk CJ, Looney RJ, and Anolik JH. Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells. Arthritis Rheum 64: 493-503, 2012.
78. Imai Y and Takahashi R. How do Parkin mutations result in neurodegeneration? Curr Opin Neurobiol 14: 384-389, 2004.
79. Imbert V, Rupec RA, Livolsi A, Pahl HL, Traenckner EB, Mueller-Dieckmann C, Farahifar D, Rossi B, Auberger P, Baeuerle PA, and Peyron JF. Tyrosine phosphorylation of I kappa B-alpha activates NF-kappa B without proteolytic degradation of I kappa B-alpha. Cell 86: 787-798, 1996.
80. Ishida A, Sasaguri T, Kosaka C, Nojima H, and Ogata J. Induction of the cyclin-dependent kinase inhibitor p21(Sdi1/Cip1/Waf1) by nitric oxide-generating vasodilator in vascular smooth muscle cells. J Biol Chem 272: 10050-10057, 1997.
81. Ishii T, Itoh K, Sato H, and Bannai S. Oxidative stressinducible proteins in macrophages. Free Radic Res 31: 351-355, 1999.
82. Ishikawa K, Sugawara D, Wang X, Suzuki K, Itabe H, Maruyama Y, and Lusis AJ. Heme oxygenase-1 inhibits atherosclerotic lesion formation in ldl-receptor knockout mice. Circ Res 88: 506-512, 2001.
83. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS, and Kaelin WG, Jr. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292: 464-468, 2001.
84. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, von Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, and Ratcliffe PJ. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292: 468-472, 2001.
85. Jahngen-Hodge J, Obin MS, Gong X, Shang F, Nowell TR, Jr., Gong J, Abasi H, Blumberg J, and Taylor A. Regulation of ubiquitin-conjugating enzymes by glutathione following oxidative stress. J Biol Chem 272: 28218-28226, 1997.
86. Jiang BH, Rue E, Wang GL, Roe R, and Semenza GL. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem 271: 17771-17778, 1996.
87. Jiang G, Li T, Qiu Y, Rui Y, Chen W, and Lou Y. RNA interference for HIF-1alpha inhibits foam cells formation in vitro. Eur J Pharmacol 562: 183-190, 2007.
88. Jo Y, Lee PC, Sguigna PV, and DeBose-Boyd RA. Sterolinduced degradation of HMG CoA reductase depends on interplay of two Insigs and two ubiquitin ligases, gp78 and Trc8. Proc Natl Acad Sci USA 108: 20503-20508, 2011.
89. Jung Y, Isaacs JS, Lee S, Trepel J, Liu ZG, and Neckers L. Hypoxia-inducible factor induction by tumour necrosis factor in normoxic cells requires receptor-interacting protein-dependent nuclear factor kappa B activation. Biochem J 370: 1011-1017, 2003.
90. Jung YJ, Isaacs JS, Lee S, Trepel J, and Neckers L. IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J 17: 2115-2117, 2003.
91. Kalim KW, Basler M, Kirk CJ, and Groettrup M. Immunoproteasome subunit LMP7 deficiency and inhibition suppresses Th1 and Th17 but enhances regulatory T cell differentiation. J Immunol 189: 4182-4193, 2012.
92. Kallio PJ, Wilson WJ, O'Brien S, Makino Y, and Poellinger L. Regulation of the hypoxia-inducible transcription factor 1alpha by the ubiquitin-proteasome pathway. J Biol Chem 274: 6519-6525, 1999.
93. Kalogeris TJ, Laroux FS, Cockrell A, Ichikawa H, Okayama N, Phifer TJ, Alexander JS, and Grisham MB. Effect of selective proteasome inhibitors on TNF-induced activation of primary and transformed endothelial cells. Am J Physiol 276: C856-C864, 1999.
94. Kapadia MR, Eng JW, Jiang Q, Stoyanovsky DA, and Kibbe MR. Nitric oxide regulates the 26S proteasome in vascular smooth muscle cells. Nitric Oxide 20: 279-288, 2009.
95. Karin M and Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 18: 621-663, 2000.
96. Kastrup CJ, Nahrendorf M, Figueiredo JL, Lee H, Kambhampati S, Lee T, Cho SW, Gorbatov R, Iwamoto Y, Dang TT, Dutta P, Yeon JH, Cheng H, Pritchard CD, Vegas AJ, Siegel CD, MacDougall S, Okonkwo M, Thai A, Stone JR, Coury AJ, Weissleder R, Langer R, and Anderson DG. Painting blood vessels and atherosclerotic plaques with an adhesive drug depot. Proc Natl Acad Sci USA 109: 21444-21449, 2012.
97. Kawashima S and Yokoyama M. Dysfunction of endothelial nitric oxide synthase and atherosclerosis. Arterioscler Thromb Vasc Biol 24: 998-1005, 2004.
98. Keller JN, Huang FF, Zhu H, Yu J, Ho YS, and Kindy TS. Oxidative stress-associated impairment of proteasome activity during ischemia-reperfusion injury. J Cereb Blood Flow Metab 20: 1467-1473, 2000.
99. Kempe S, Kestler H, Lasar A, and Wirth T. NF-kappaB controls the global pro-inflammatory response in endothelial cells: evidence for the regulation of a pro-atherogenic program. Nucleic Acids Res 33: 5308-5319, 2005.
100. Kikuchi J, Furukawa Y, Kubo N, Tokura A, Hayashi N, Nakamura M, Matsuda M, and Sakurabayashi I. Induction of ubiquitin-conjugating enzyme by aggregated low density lipoprotein in human macrophages and its implications for atherosclerosis. Arterioscler Thromb Vasc Biol 20: 128-134, 2000.
101. Kim HH and Kim K. Enhancement of TNF-alphamediated cell death in vascular smooth muscle cells through cytochrome c-independent pathway by the proteasome inhibitor. FEBS Lett 535: 190-194, 2003.
102. Kim SC, Rho MC, Lee HS, Kim YK, and Kim K. Caspase-3-dependent apoptosis in vascular smooth muscle cell by proteasome inhibition. J Cardiovasc Pharmacol 42: 554-560, 2003.
103. Kirkin V, McEwan DG, Novak I, and Dikic I. A role for ubiquitin in selective autophagy. Mol Cell 34: 259-269, 2009.
104. Kisselev AF, Callard A, and Goldberg AL. Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate. J Biol Chem 281: 8582-8590, 2006.
105. Kisselev AF, van der Linden WA, and Overkleeft HS. Proteasome inhibitors: an expanding army attacking a unique target. Chem Biol 19: 99-115, 2012.
106. Kleindienst R, Xu Q, Willeit J, Waldenberger FR, Weimann S, and Wick G. Immunology of atherosclerosis. Demonstration of heat shock protein 60 expression and T lymphocytes bearing alpha/beta or gamma/delta receptor in human atherosclerotic lesions. Am J Pathol 142: 1927-1937, 1993.
107. Kloetzel PM and Ossendorp F. Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. Curr Opin Immunol 16: 76-81, 2004.
108. Kloss A, Meiners S, Ludwig A, and Dahlmann B. Multiple cardiac proteasome subtypes differ in their susceptibility to proteasome inhibitors. Cardiovasc Res 85: 367-375, 2010.
109. Knowlton JR, Johnston SC, Whitby FG, Realini C, Zhang Z, Rechsteiner M, and Hill CP. Structure of the proteasome activator REGalpha (PA28alpha). Nature 390: 639-643, 1997.
110. Kotamraju S, Matalon S, Matsunaga T, Shang T, Hickman-Davis JM, and Kalyanaraman B. Upregulation of immunoproteasomes by nitric oxide: potential antioxidative mechanism in endothelial cells. Free Radic Biol Med 40: 1034-1044, 2006.
111. Kotamraju S, Tampo Y, Keszler A, Chitambar CR, Joseph J, Haas AL, and Kalyanaraman B. Nitric oxide inhibits H2O2-induced transferrin receptor-dependent apoptosis in endothelial cells: Role of ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 100: 10653-10658, 2003.
112. Kvietys PR and Granger DN. Role of reactive oxygen and nitrogen species in the vascular responses to inflammation. Free Radic Biol Med 52: 556-592, 2012.
113. Lamark T and Johansen T. Autophagy: links with the proteasome. Curr Opin Cell Biol 22: 192-198, 2010.
114. Lin SJ, Shyue SK, Hung YY, Chen YH, Ku HH, Chen JW, Tam KB, and Chen YL. Superoxide dismutase inhibits the expression of vascular cell adhesion molecule-1 and intracellular cell adhesion molecule-1 induced by tumor necrosis factor-alpha in human endothelial cells through the JNK/p38 pathways. Arterioscler Thromb Vasc Biol 25: 334-340, 2005.
115. Liu H, Yu S, Xu W, and Xu J. Enhancement of 26S proteasome functionality connects oxidative stress and vascular endothelial inflammatory response in diabetes mellitus. Arterioscler Thromb Vasc Biol 32: 2131-2140, 2012.
116. Lorenz M, Wilck N, Meiners S, Ludwig A, Baumann G, Stangl K, and Stangl V. Proteasome inhibition prevents experimentally-induced endothelial dysfunction. Life Sci 84: 929-934, 2009.
117. Ludwig A, Fechner M, Wilck N, Meiners S, Grimbo N, Baumann G, Stangl V, and Stangl K. Potent antiinflammatory effects of low-dose proteasome inhibition in the vascular system. J Mol Med (Berl) 87: 793-802, 2009.
118. Ludwig A and Meiners S. Targeting of the proteasome worsens atherosclerosis? Circ Res 102: E37-E37, 2008.
119. Ma CP, Slaughter CA, and DeMartino GN. Identification, purification, and characterization of a protein activator PA28) of the 20 S proteasome (macropain). J Biol Chem 267: 10515-10523, 1992.
120. Maiuri MC, Grassia G, Platt AM, Carnuccio R, Ialenti A, and Maffia P. Macrophage autophagy in atherosclerosis. Mediators Inflamm 2013: 584715, 2013.
121. Marfella R, D'Amico M, Di Filippo C, Baldi A, Siniscalchi M, Sasso FC, Portoghese M, Carbonara O, Crescenzi B, Sangiuolo P, Nicoletti GF, Rossiello R, Ferraraccio F, Cacciapuoti F, Verza M, Coppola L, Rossi F, and Paolisso G. Increased activity of the ubiquitinproteasome system in patients with symptomatic carotid disease is associated with enhanced inflammation and may destabilize the atherosclerotic plaque: effects of rosiglitazone treatment. J Am Coll Cardiol 47: 2444-2455, 2006.
122. Marfella R, D'Amico M, Esposito K, Baldi A, Di Filippo C, Siniscalchi M, Sasso FC, Portoghese M, Cirillo F, Cacciapuoti F, Carbonara O, Crescenzi B, Baldi F, Ceriello A, Nicoletti GF, D'Andrea F, Verza M, Coppola L, Rossi F, and Giugliano D. The ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques: effects of rosiglitazone treatment. Diabetes 55: 622-632, 2006.
123. Marfella R, Di Filippo C, Laieta MT, Vestini R, Barbieri M, Sangiulo P, Crescenzi B, Ferraraccio F, Rossi F, D'Amico M, and Paolisso G. Effects of ubiquitinproteasome system deregulation on the vascular senescence and atherosclerosis process in elderly patients. J Gerontol A Biol Sci Med Sci 63: 200-203, 2008.
124. Marfella R, Di Filippo C, Portoghese M, Ferraraccio F, Crescenzi B, Siniscalchi M, Barbieri M, Bologna C, Rizzo MR, Rossi F, D'Amico M, and Paolisso G. Proteasome activity as a target of hormone replacement therapydependent plaque stabilization in postmenopausal women. Hypertension 51: 1135-1141, 2008.
125. Marfella R, Siniscalchi M, Portoghese M, Di Filippo C, Ferraraccio F, Schiattarella C, Crescenzi B, Sangiuolo P, Ferraro G, Siciliano S, Cinone F, Mazzarella G, Martis S, Verza M, Coppola L, Rossi F, D'Amico M, and Paolisso G. Morning blood pressure surge as a destabilizing factor of atherosclerotic plaque: role of ubiquitin-proteasome activity. Hypertension 49: 784-791, 2007.
126. Martinet W and Kockx MM. Apoptosis in atherosclerosis: focus on oxidized lipids and inflammation. Curr Opin Lipidol 12: 535-541, 2001.
127. Martinet W, Schrijvers DM, and De Meyer GR. Necrotic cell death in atherosclerosis. Basic Res Cardiol 106: 749-760, 2011.
128. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, and Ratcliffe PJ. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271-275, 1999.
129. Meiners S, Laule M, Rother W, Guenther C, Prauka I, Muschick P, Baumann G, Kloetzel PM, and Stangl K. Ubiquitin-proteasome pathway as a new target for the prevention of restenosis. Circulation 105: 483-489, 2002.
130. Meiners S, Ludwig A, Lorenz M, Dreger H, Baumann G, Stangl V, and Stangl K. Nontoxic proteasome inhibition activates a protective antioxidant defense response in endothelial cells. Free Radic Biol Med 40: 2232-2241, 2006.
131. Meiners S, Ludwig A, Stangl V, and Stangl K. Proteasome inhibitors: poisons and remedies. Med Res Rev 28: 309-327, 2008.
132. Meister S, Schubert U, Neubert K, Herrmann K, Burger R, Gramatzki M, Hahn S, Schreiber S, Wilhelm S, Herrmann M, Jack HM, and Voll RE. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res 67: 1783-1792, 2007.
133. Mezquita J, Mezquita B, Pau M, and Mezquita C. Downregulation of Flt-1 gene expression by the proteasome inhibitor MG262. J Cell Biochem 89: 1138-1147, 2003.
134. Monaco C, Andreakos E, Kiriakidis S, Mauri C, Bicknell C, Foxwell B, Cheshire N, Paleolog E, and Feldmann M. Canonical pathway of nuclear factor kappa B activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis. Proc Natl Acad Sci USA 101: 5634-5639, 2004.
135. Muchamuel T, Basler M, Aujay MA, Suzuki E, Kalim KW, Lauer C, Sylvain C, Ring ER, Shields J, Jiang J, Shwonek P, Parlati F, Demo SD, Bennett MK, Kirk CJ, and Groettrup M. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med 15: 781-787, 2009.
136. Nakayama KI and Nakayama K. Ubiquitin ligases: cellcycle control and cancer. Nat Rev Cancer 6: 369-381, 2006.
137. Nathan JA, Spinnenhirn V, Schmidtke G, Basler M, Groettrup M, and Goldberg AL. Immuno-and constitutive proteasomes do not differ in their abilities to degrade ubiquitinated proteins. Cell 152: 1184-1194, 2013.
138. Navon A and Goldberg AL. Proteins are unfolded on the surface of the ATPase ring before transport into the proteasome. Mol Cell 8: 1339-1349, 2001.
139. Neutzner A, Li S, Xu S, and Karbowski M. The ubiquitin/proteasome system-dependent control of mitochondrial steps in apoptosis. Semin Cell Dev Biol 23: 499-508, 2012.
140. Newby AC. Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability. Arterioscler Thromb Vasc Biol 28: 2108-2114, 2008.
141. Obin M, Shang F, Gong X, Handelman G, Blumberg J, and Taylor A. Redox regulation of ubiquitin-conjugating enzymes: mechanistic insights using the thiol-specific oxidant diamide. FASEB J 12: 561-569, 1998.
142. Ogura M, Ayaori M, Terao Y, Hisada T, Iizuka M, Takiguchi S, Uto-Kondo H, Yakushiji E, Nakaya K, Sasaki M, Komatsu T, Ozasa H, Ohsuzu F, and Ikewaki K. Proteasomal inhibition promotes ATP-binding cassette transporter A1 (ABCA1) and ABCG1 expression and cholesterol efflux from macrophages in vitro and in vivo. Arterioscler Thromb Vasc Biol 31: 1980-1987, 2011.
143. Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, Pavletich N, Chau V, and Kaelin WG. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2: 423-427, 2000.
144. Ohkita M, Takaoka M, Kobayashi Y, Itoh E, Uemachi H, and Matsumura Y. Involvement of proteasome in endothelin-1 production in cultured vascular endothelial cells. Jpn J Pharmacol 88: 197-205, 2002.
145. Okada K, Wangpoengtrakul C, Osawa T, Toyokuni S, Tanaka K, and Uchida K. 4-Hydroxy-2-nonenal-mediated impairment of intracellular proteolysis during oxidative stress. Identification of proteasomes as target molecules. J Biol Chem 274: 23787-23793, 1999.
146. Oliver KM, Taylor CT, and Cummins EP. Hypoxia. Regulation of NFkappaB signalling during inflammation: the role of hydroxylases. Arthritis Res Ther 11: 215, 2009.
147. Ortiz-Lazareno PC, Hernandez-Flores G, Dominguez-Rodriguez JR, Lerma-Diaz JM, Jave-Suarez LF, Aguilar-Lemarroy A, Gomez-Contreras PC, Scott-Algara D, and Bravo-Cuellar A. MG132 proteasome inhibitor modulates proinflammatory cytokines production and expression of their receptors in U937 cells: involvement of nuclear factor-kappaB and activator protein-1. Immunology 124: 534-541, 2008.
148. Ostrowska JK, Wojtukiewicz MZ, Chabielska E, Buczko W, and Ostrowska H. Proteasome inhibitor prevents experimental arterial thrombosis in renovascular hypertensive rats. Thromb Haemost 92: 171-177, 2004.
149. Palombella VJ, Rando OJ, Goldberg AL, and Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 78: 773-785, 1994.
150. Powell SR, Herrmann J, Lerman A, Patterson C, and Wang X. The ubiquitin-proteasome system and cardiovascular disease. Prog Mol Biol Transl Sci 109: 295-346, 2012.
151. Queisser MA, Yao D, Geisler S, Hammes HP, Lochnit G, Schleicher ED, Brownlee M, and Preissner KT. Hyperglycemia impairs proteasome function by methylglyoxal. Diabetes 59: 670-678, 2010.
152. Qureshi N, Vogel SN, Van Way C, 3rd, Papasian CJ, Qureshi AA, and Morrison DC. The proteasome: a central regulator of inflammation and macrophage function. Immunol Res 31: 243-260, 2005.
153. Ravid T, Doolman R, Avner R, Harats D, and Roitelman J. The ubiquitin-proteasome pathway mediates the regulated degradation of mammalian 3-hydroxy-3-methylglutarylcoenzyme A reductase. J Biol Chem 275: 35840-35847, 2000.
154. Read MA, Neish AS, Luscinskas FW, Palombella VJ, Maniatis T, and Collins T. The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression. Immunity 2: 493-506, 1995.
155. Reed SI. Ratchets and clocks: the cell cycle, ubiquitylation and protein turnover. Nat Rev Mol Cell Biol 4: 855-864, 2003.
156. Rocken C, Tautenhahn J, Buhling F, Sachwitz D, Vockler S, Goette A, and Burger T. Prevalence and pathology of amyloid in atherosclerotic arteries. Arterioscler Thromb Vasc Biol 26: 676-677, 2006.
157. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340: 115-126, 1999.
158. Saccani S, Marazzi I, Beg AA, and Natoli G. Degradation of promoter-bound p65/RelA is essential for the prompt termination of the nuclear factor kappaB response. J Exp Med 200: 107-113, 2004.
159. Sadaka B, Alloway RR, Shields AR, Schmidt NM, and Woodle ES. Proteasome inhibition for antibody-mediated allograft rejection. Semin Hematol 49: 263-269, 2012.
160. Salceda S and Caro J. Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitinproteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 272: 22642-22647, 1997.
161. Schrijvers DM, De Meyer GR, and Martinet W. Autophagy in atherosclerosis: a potential drug target for plaque stabilization. Arterioscler Thromb Vasc Biol 31: 2787-2791, 2011.
162. Scruggs SB, Zong NC, Wang D, Stefani E, and Ping P. Post-translational modification of cardiac proteasomes: functional delineation enabled by proteomics. Am J Physiol Heart Circ Physiol 303: H9-H18, 2012.
163. Seifert U, Bialy LP, Ebstein F, Bech-Otschir D, Voigt A, Schroter F, Prozorovski T, Lange N, Steffen J, Rieger M, Kuckelkorn U, Aktas O, Kloetzel PM, and Kruger E. Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress. Cell 142: 613-624, 2010.
164. Sesso HD, Buring JE, Christen WG, Kurth T, Belanger C, MacFadyen J, Bubes V, Manson JE, Glynn RJ, and Gaziano JM. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA 300: 2123-2133, 2008.
165. Shabaneh TB, Downey SL, Goddard AL, Screen M, Lucas MM, Eastman A, and Kisselev AF. Molecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib. PLoS One 8: e56132, 2013.
166. Shen Y, Zhou X, Wang Z, Yang G, Jiang Y, Sun C, Wang J, Tong Y, and Guo H. Coagulation profiles and thromboembolic events of bortezomib plus thalidomide and dexamethasone therapy in newly diagnosed multiple myeloma. Leuk Res 35: 147-151, 2011.
167. Shringarpure R, Grune T, Mehlhase J, and Davies KJ. Ubiquitin conjugation is not required for the degradation of oxidized proteins by proteasome. J Biol Chem 278: 311-318, 2003.
168. Sitte N, Huber M, Grune T, Ladhoff A, Doecke WD, Von Zglinicki T, and Davies KJ. Proteasome inhibition by lipofuscin/ceroid during postmitotic aging of fibroblasts. FASEB J 14: 1490-1498, 2000.
169. Sluimer JC, Gasc JM, van Wanroij JL, Kisters N, Groeneweg M, Sollewijn Gelpke MD, Cleutjens JP, van den Akker LH, Corvol P, Wouters BG, Daemen MJ, and Bijnens AP. Hypoxia, hypoxia-inducible transcription factor, and macrophages in human atherosclerotic plaques are correlated with intraplaque angiogenesis. J Am Coll Cardiol 51: 1258-1265, 2008.
170. Smith DM, Kafri G, Cheng Y, Ng D, Walz T, and Goldberg AL. ATP binding to PAN or the 26S ATPases causes association with the 20S proteasome, gate opening, and translocation of unfolded proteins. Mol Cell 20: 687-698, 2005.
171. Stangl K and Stangl V. The ubiquitin-proteasome pathway and endothelial (dys)function. Cardiovasc Res 85: 281-290, 2010.
172. Stangl V, Lorenz M, Meiners S, Ludwig A, Bartsch C, Moobed M, Vietzke A, Kinkel HT, Baumann G, and Stangl K. Long-term up-regulation of eNOS and improvement of endothelial function by inhibition of the ubiquitin-proteasome pathway. FASEB J 18: 272-279, 2004.
173. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W, Jr., Rosenfeld ME, Schwartz CJ, Wagner WD, and Wissler RW. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 92: 1355-1374, 1995.
174. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W, Jr., Rosenfeld ME, Schwartz CJ, Wagner WD, and Wissler RW. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler Thromb Vasc Biol 15: 1512-1531, 1995.
175. Sun R, Xiao L, and Duan S. High expression of ubiquitin conjugates and NF-kappaB in unstable human intracranial atherosclerotic plaques. J Cell Physiol 227: 784-788, 2012.
176. Sun SC. Non-canonical NF-kappaB signaling pathway. Cell Res 21: 71-85, 2011.
177. Tabas I and Glass CK. Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science 339: 166-172, 2013.
178. Tanimoto K, Makino Y, Pereira T, and Poellinger L. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J 19: 4298-4309, 2000.
179. Tardif JC, Gregoire J, L'Allier PL, Ibrahim R, Anderson TJ, Reeves F, Title LM, Schampaert E, LeMay M, Lesperance J, Scott R, Guertin MC, Brennan ML, Hazen SL, Bertrand OF; CART-2 Investigators. Effects of the antioxidant succinobucol (AGI-1067) on human atherosclerosis in a randomized clinical trial. Atherosclerosis 197: 480-486, 2008.
180. Tardif JC, McMurray JJ, Klug E, Small R, Schumi J, Choi J, Cooper J, Scott R, Lewis EF, L'Allier PL, Pfeffer MA; Aggressive Reduction of Inflammation Stops Events Trial I. Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebocontrolled trial. Lancet 371: 1761-1768, 2008.
181. Teoh CL, Griffin MD, and Howlett GJ. Apolipoproteins and amyloid fibril formation in atherosclerosis. Protein Cell 2: 116-127, 2011.
182. Thomas S, Kotamraju S, Zielonka J, Harder DR, and Kalyanaraman B. Hydrogen peroxide induces nitric oxide and proteosome activity in endothelial cells: a bell-shaped signaling response. Free Radic Biol Med 42: 1049-1061, 2007.
183. Thyberg J and Blomgren K. Effects of proteasome and calpain inhibitors on the structural reorganization and proliferation of vascular smooth muscle cells in primary culture. Lab Invest 79: 1077-1088, 1999.
184. Tribble DL, Barcellos-Hoff MH, Chu BM, and Gong EL. Ionizing radiation accelerates aortic lesion formation in fat-fed mice via SOD-inhibitable processes. Arterioscler Thromb Vasc Biol 19: 1387-1392, 1999.
185. Tsai YC, Leichner GS, Pearce MM, Wilson GL, Wojcikiewicz RJ, Roitelman J, and Weissman AM. Differential regulation of HMG-CoA reductase and Insig-1 by enzymes of the ubiquitin-proteasome system. Mol Biol Cell 23: 4484-4494, 2012.
186. Tsihlis ND, Kapadia MR, Vavra AK, Flannery WD, Oustwani CS, Jiang Q, and Kibbe MR. Nitric oxide may inhibit neointimal hyperplasia by decreasing isopeptidase T levels and activity in the vasculature. J Vasc Surg 58: 179-186, 2013.
187. Tsihlis ND, Kapadia MR, Vavra AK, Jiang Q, Fu B, Martinez J, and Kibbe MR. Nitric oxide decreases activity and levels of the 11S proteasome activator PA28 in the vasculature. Nitric Oxide 27: 50-58, 2012.
188. Van Herck JL, De Meyer GR, Martinet W, Bult H, Vrints CJ, and Herman AG. Proteasome inhibitor bortezomib promotes a rupture-prone plaque phenotype in ApoEdeficient mice. Basic Res Cardiol 105: 39-50, 2010.
189. Van Vre EA, Ait-Oufella H, Tedgui A, and Mallat Z. Apoptotic cell death and efferocytosis in atherosclerosis. Arterioscler Thromb Vasc Biol 32: 887-893, 2012.
190. Versari D, Herrmann J, Gossl M, Mannheim D, Sattler K, Meyer FB, Lerman LO, and Lerman A. Dysregulation of the ubiquitin-proteasome system in human carotid atherosclerosis. Arterioscler Thromb Vasc Biol 26: 2132-2139, 2006.
191. Vieira O, Escargueil-Blanc I, Jurgens G, Borner C, Almeida L, Salvayre R, and Negre-Salvayre A. Oxidized LDLs alter the activity of the ubiquitin-proteasome pathway: potential role in oxidized LDL-induced apoptosis. FASEB J 14: 532-542, 2000.
192. Voges D, Zwickl P, and Baumeister W. The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu Rev Biochem 68: 1015-1068, 1999.
193. Wang GL, Jiang BH, Rue EA, and Semenza GL. Hypoxiainducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 92: 5510-5514, 1995.
194. Wang JC and Bennett M. Aging and atherosclerosis: mechanisms, functional consequences, and potential therapeutics for cellular senescence. Circ Res 111: 245-259, 2012.
195. Wang X, Yen J, Kaiser P, and Huang L. Regulation of the 26S proteasome complex during oxidative stress. Sci Signal 3: ra88, 2010.
196. Wei Q and Xia Y. Proteasome inhibition down-regulates endothelial nitric-oxide synthase phosphorylation and function. J Biol Chem 281: 21652-21659, 2006.
197. Wilck N, Fechner M, Dreger H, Hewing B, Arias A, Meiners S, Baumann G, Stangl V, Stangl K, and Ludwig A. Attenuation of early atherogenesis in low-density lipoprotein receptor-deficient mice by proteasome inhibition. Arterioscler Thromb Vasc Biol 32: 1418-1426, 2012.
198. Wu M, Bian Q, Liu Y, Fernandes AF, Taylor A, Pereira P, and Shang F. Sustained oxidative stress inhibits NFkappaB activation partially via inactivating the proteasome. Free Radic Biol Med 46: 62-69, 2009.
199. Wu YJ, Sala-Newby GB, Shu KT, Yeh HI, Nakayama KI, Nakayama K, Newby AC, and Bond M. S-phase kinaseassociated protein-2 (Skp2) promotes vascular smooth muscle cell proliferation and neointima formation in vivo. J Vasc Surg 50: 1135-1142, 2009.
200. Xie P, Fan Y, Zhang H, Zhang Y, She M, Gu D, Patterson C, and Li H. CHIP represses myocardin-induced smooth muscle cell differentiation via ubiquitin-mediated proteasomal degradation. Mol Cell Biol 29: 2398-2408, 2009.
201. Xu J, Wang S, Wu Y, Song P, and Zou MH. Tyrosine nitration of PA700 activates the 26S proteasome to induce endothelial dysfunction in mice with angiotensin II-induced hypertension. Hypertension 54: 625-632, 2009.
202. Xu J, Wang S, Zhang M, Wang Q, Asfa S, and Zou MH. Tyrosine nitration of PA700 links proteasome activation to endothelial dysfunction in mouse models with cardiovascular risk factors. PLoS One 7: e29649, 2012.
203. Xu J, Wu Y, Song P, Zhang M, Wang S, and Zou MH. Proteasome-dependent degradation of guanosine 5¢-triphosphate cyclohydrolase I causes tetrahydrobiopterin deficiency in diabetes mellitus. Circulation 116: 944-953, 2007.
204. Yao D, Gu Z, Nakamura T, Shi ZQ, Ma Y, Gaston B, Palmer LA, Rockenstein EM, Zhang Z, Masliah E, Uehara T, and Lipton SA. Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. Proc Natl Acad Sci USA 101: 10810-10814, 2004.
205. Zangari M, Guerrero J, Cavallo F, Prasad HK, Esseltine D, and Fink L. Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma. Haematologica 93: 953-954, 2008.
206. Zhou J, Lhotak S, Hilditch BA, and Austin RC. Activation of the unfolded protein response occurs at all stages of atherosclerotic lesion development in apolipoprotein Edeficient mice. Circulation 111: 1814-1821, 2005.